目的:探究溴结构域蛋白4(bromodomain-containing protein 4,BRD4)在心肌梗死后心脏损伤中的作用。方法:通过分析公共数据,明确心肌梗死小鼠心脏组织中BRD4在整体和以及各细胞群中的表达变化。构建心肌梗死小鼠模型,设立空白对照组(WT...目的:探究溴结构域蛋白4(bromodomain-containing protein 4,BRD4)在心肌梗死后心脏损伤中的作用。方法:通过分析公共数据,明确心肌梗死小鼠心脏组织中BRD4在整体和以及各细胞群中的表达变化。构建心肌梗死小鼠模型,设立空白对照组(WT组),心肌梗死组(MI组),药物组(JQ1组,ABBV-744组),术后第6天腹腔注射BRD4抑制剂JQ1或灌胃二代抑制剂ABBV-744,持续22天。MI术后4周,小动物超声影像系统检测小鼠心功能,检测小鼠质量、心脏质量与胫骨长度,天狼星红染色评估梗死区纤维化程度,WGA染色检测心肌细胞横截面积。结果:与心肌梗死组相比,BRD4抑制剂组能够显著改善术后心功能障碍(P<0.01)。转录组学数据表明,BRD4在心肌梗死损伤区域持续高表达。单细胞数据显示,心肌梗死后,成纤维细胞中BRD4阳性细胞比例显著增加,并且在心肌梗死后7、14、30d的成纤维细胞中,BRD4表达持续上调。与心肌梗死组相比,BRD4抑制剂组显著减轻心脏纤维化(P <0.01)。与一代药物组相比,二代药物组心脏纤维化程度显著降低(P<0.01)。结论:抑制表观转录因子BRD4可减轻心肌梗死后心脏损伤,抑制心脏纤维化,并改善心功能。展开更多
心血管疾病(cardiovascular diseases)一直以来都是我国乃至全球疾病负担的主要原因,其生存率低,发病率一直呈现上升趋势[1]。据推测,我国目前心血管疾病患者高达3亿,导致的死亡人数约占全国死亡人数的40%,有数据显示,我国每年因心血管...心血管疾病(cardiovascular diseases)一直以来都是我国乃至全球疾病负担的主要原因,其生存率低,发病率一直呈现上升趋势[1]。据推测,我国目前心血管疾病患者高达3亿,导致的死亡人数约占全国死亡人数的40%,有数据显示,我国每年因心血管疾病产生的费用高达1700亿元,给医疗卫生保健资源带来了极大的负担[2-3]。心血管疾病涉及冠心病、心律失常、高血压、心肌病和心力衰竭等,虽然临床表现存在差异,但在发病机制中仍有许多相似之处。溴结构域和额外终端域(bromodomain and extra-terminal domain,BET)家族蛋白是一种表观遗传调控蛋白,由含溴结构域蛋白2(bromodomain-containing protein 2,BRD2)、BRD3、BRD4和睾丸特异性含溴结构域蛋白(testis-specific bromodomain-containing protein,BRDT)组成[4]。展开更多
Bromodomain结构域蛋白4(bromodomain-containing protein 4,BRD4)已成为治疗多种疾病药物设计的重要靶标.最近在实验上发现了几种有效的靶向BRD4的抑制剂,但具体的抑制机理尚不清楚.此工作采用分子动力学模拟,动态相关性分析和结合自...Bromodomain结构域蛋白4(bromodomain-containing protein 4,BRD4)已成为治疗多种疾病药物设计的重要靶标.最近在实验上发现了几种有效的靶向BRD4的抑制剂,但具体的抑制机理尚不清楚.此工作采用分子动力学模拟,动态相关性分析和结合自由能计算研究抑制剂8Q9和8QC与BRD4(1)的结合模式.分子动力学分析表明抑制剂结合对BRD4(1)的结构柔性产生重大影响.同时动态相关性分析进一步表明抑制剂结合极大地改变了BRD4(1)的运动模式.结合自由能计算结果表明范德华相互作用是抑制剂与BRD4(1)结合的主要驱动力.采用基于残基的自由能分解方法评估了分离残基对抑制剂结合的贡献,数据表明氢键相互作用和疏水相互作用是影响抑制剂与BRD4(1)结合的关键因素.本研究有望为设计和开发靶向BRD4的抑制剂提供有意义的理论指导.展开更多
OBJECTIVE To discover a small-molecule bromodomain-containing protein 4(BRD4)inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer and exploreits potential mech...OBJECTIVE To discover a small-molecule bromodomain-containing protein 4(BRD4)inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer and exploreits potential mechanisms.METHODS BRD4 interactors were analyzed by PPI network prediction and The Cancer Genome Atlas(TCGA)analysis.The interaction between BRD4 and AMPK was confirmed by co-immunoprecipitation assay.Novel BRD4 inhibitors were designed and synthesized based upon pharmacophore analysis of BRD4(1),then screened by antiproliferative activity and Alpha Screen of BRD4(1).The selectivity of the best candidate compound 8f was validated by co-crystallization,FRET assay and co-immuno precipitation assay.The mechanisms of 8f were investigated by fluorescence microscopy,electron microscopy,Western blotting,immunocytochemistry,si RNA and GFP-m RFP-LC3 plasmid transfections,as well as immunohistochemistry and immunofluorescence.Potential mechanisms were discovered by i TRAQ-based proteomics analysis and the therapeutic effect of 8f was assessed by xenograft breast cancer mouse and zebrafish models.RESULTS We identified that BRD4 interacted with AMPK,which was remarkably downregulated in breast cancer.We next designed and synthesized 49 candidate compounds,and eventually discovered a selective small-molecule inhibitor of BRD4(8f).Subsequently,8f was discovered to induce autophagyassociated cell death(ACD)by BRD4-AMPK interaction,and thus activating AMPK-m TOR-ULK1-modulated autophagic pathway in breast cancer cells.Interestingly,the i TRAQ-based proteomics analyses revealed that 8f induced ACD pathways,involved in HMGB1,VDAC1/2 and e EF2.Moreover,8f displayed a therapeutic potential on both xenograft breast cancer mouse and zebrafish models.CONCLUSION We discovered a novel small-molecule inhibitor of BRD4 that induces BRD4-AMPK-modulated ACD in breast cancer,which may provide a candidate drug for future cancer therapy.展开更多
糖尿病是一组由多病因引起的以慢性高血糖为特征的代谢性疾病,是由于胰岛素分泌不足和(或)利用缺陷所引起的。体内长期碳水化合物、脂肪、蛋白质代谢紊乱,可引起多系统损害,导致眼、肾、神经、心脏、血管等组织器官出现慢性进行性病变...糖尿病是一组由多病因引起的以慢性高血糖为特征的代谢性疾病,是由于胰岛素分泌不足和(或)利用缺陷所引起的。体内长期碳水化合物、脂肪、蛋白质代谢紊乱,可引起多系统损害,导致眼、肾、神经、心脏、血管等组织器官出现慢性进行性病变、功能减退及衰竭。研究发现,溴结构域蛋白4(Bromodomain-containing protein 4,BRD4)在糖尿病及其并发症中发挥重要作用,它可识别并结合于靶基因的启动子区域,促进目的基因表达,从而调控糖尿病及其并发症的发生发展。因此,靶向抑制BRD4的表达,可能为治疗糖尿病提供了一种新的治疗途径。本文对BRD4在糖尿病及其并发症中的作用进行总结,强调针对BRD4的表观遗传学治疗策略在糖尿病及其并发症治疗中的潜力。展开更多
文摘目的:探究溴结构域蛋白4(bromodomain-containing protein 4,BRD4)在心肌梗死后心脏损伤中的作用。方法:通过分析公共数据,明确心肌梗死小鼠心脏组织中BRD4在整体和以及各细胞群中的表达变化。构建心肌梗死小鼠模型,设立空白对照组(WT组),心肌梗死组(MI组),药物组(JQ1组,ABBV-744组),术后第6天腹腔注射BRD4抑制剂JQ1或灌胃二代抑制剂ABBV-744,持续22天。MI术后4周,小动物超声影像系统检测小鼠心功能,检测小鼠质量、心脏质量与胫骨长度,天狼星红染色评估梗死区纤维化程度,WGA染色检测心肌细胞横截面积。结果:与心肌梗死组相比,BRD4抑制剂组能够显著改善术后心功能障碍(P<0.01)。转录组学数据表明,BRD4在心肌梗死损伤区域持续高表达。单细胞数据显示,心肌梗死后,成纤维细胞中BRD4阳性细胞比例显著增加,并且在心肌梗死后7、14、30d的成纤维细胞中,BRD4表达持续上调。与心肌梗死组相比,BRD4抑制剂组显著减轻心脏纤维化(P <0.01)。与一代药物组相比,二代药物组心脏纤维化程度显著降低(P<0.01)。结论:抑制表观转录因子BRD4可减轻心肌梗死后心脏损伤,抑制心脏纤维化,并改善心功能。
文摘心血管疾病(cardiovascular diseases)一直以来都是我国乃至全球疾病负担的主要原因,其生存率低,发病率一直呈现上升趋势[1]。据推测,我国目前心血管疾病患者高达3亿,导致的死亡人数约占全国死亡人数的40%,有数据显示,我国每年因心血管疾病产生的费用高达1700亿元,给医疗卫生保健资源带来了极大的负担[2-3]。心血管疾病涉及冠心病、心律失常、高血压、心肌病和心力衰竭等,虽然临床表现存在差异,但在发病机制中仍有许多相似之处。溴结构域和额外终端域(bromodomain and extra-terminal domain,BET)家族蛋白是一种表观遗传调控蛋白,由含溴结构域蛋白2(bromodomain-containing protein 2,BRD2)、BRD3、BRD4和睾丸特异性含溴结构域蛋白(testis-specific bromodomain-containing protein,BRDT)组成[4]。
文摘Bromodomain结构域蛋白4(bromodomain-containing protein 4,BRD4)已成为治疗多种疾病药物设计的重要靶标.最近在实验上发现了几种有效的靶向BRD4的抑制剂,但具体的抑制机理尚不清楚.此工作采用分子动力学模拟,动态相关性分析和结合自由能计算研究抑制剂8Q9和8QC与BRD4(1)的结合模式.分子动力学分析表明抑制剂结合对BRD4(1)的结构柔性产生重大影响.同时动态相关性分析进一步表明抑制剂结合极大地改变了BRD4(1)的运动模式.结合自由能计算结果表明范德华相互作用是抑制剂与BRD4(1)结合的主要驱动力.采用基于残基的自由能分解方法评估了分离残基对抑制剂结合的贡献,数据表明氢键相互作用和疏水相互作用是影响抑制剂与BRD4(1)结合的关键因素.本研究有望为设计和开发靶向BRD4的抑制剂提供有意义的理论指导.
基金supported by National Natural Science Foundation of China(81473091,81673290 and U1603123)
文摘OBJECTIVE To discover a small-molecule bromodomain-containing protein 4(BRD4)inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer and exploreits potential mechanisms.METHODS BRD4 interactors were analyzed by PPI network prediction and The Cancer Genome Atlas(TCGA)analysis.The interaction between BRD4 and AMPK was confirmed by co-immunoprecipitation assay.Novel BRD4 inhibitors were designed and synthesized based upon pharmacophore analysis of BRD4(1),then screened by antiproliferative activity and Alpha Screen of BRD4(1).The selectivity of the best candidate compound 8f was validated by co-crystallization,FRET assay and co-immuno precipitation assay.The mechanisms of 8f were investigated by fluorescence microscopy,electron microscopy,Western blotting,immunocytochemistry,si RNA and GFP-m RFP-LC3 plasmid transfections,as well as immunohistochemistry and immunofluorescence.Potential mechanisms were discovered by i TRAQ-based proteomics analysis and the therapeutic effect of 8f was assessed by xenograft breast cancer mouse and zebrafish models.RESULTS We identified that BRD4 interacted with AMPK,which was remarkably downregulated in breast cancer.We next designed and synthesized 49 candidate compounds,and eventually discovered a selective small-molecule inhibitor of BRD4(8f).Subsequently,8f was discovered to induce autophagyassociated cell death(ACD)by BRD4-AMPK interaction,and thus activating AMPK-m TOR-ULK1-modulated autophagic pathway in breast cancer cells.Interestingly,the i TRAQ-based proteomics analyses revealed that 8f induced ACD pathways,involved in HMGB1,VDAC1/2 and e EF2.Moreover,8f displayed a therapeutic potential on both xenograft breast cancer mouse and zebrafish models.CONCLUSION We discovered a novel small-molecule inhibitor of BRD4 that induces BRD4-AMPK-modulated ACD in breast cancer,which may provide a candidate drug for future cancer therapy.
文摘糖尿病是一组由多病因引起的以慢性高血糖为特征的代谢性疾病,是由于胰岛素分泌不足和(或)利用缺陷所引起的。体内长期碳水化合物、脂肪、蛋白质代谢紊乱,可引起多系统损害,导致眼、肾、神经、心脏、血管等组织器官出现慢性进行性病变、功能减退及衰竭。研究发现,溴结构域蛋白4(Bromodomain-containing protein 4,BRD4)在糖尿病及其并发症中发挥重要作用,它可识别并结合于靶基因的启动子区域,促进目的基因表达,从而调控糖尿病及其并发症的发生发展。因此,靶向抑制BRD4的表达,可能为治疗糖尿病提供了一种新的治疗途径。本文对BRD4在糖尿病及其并发症中的作用进行总结,强调针对BRD4的表观遗传学治疗策略在糖尿病及其并发症治疗中的潜力。
